I know about them which was why I said you were trying to be mislead the available fund by not including the foot note which you purposely cut out from your screen shot. It's in relation to 2023.
Embarrassing is someone who put a $600M MC target (aka "bet) on just starting Ph1 clinical trial for their only IP lol. And no, I don't place any value on RC110 which was already approved to use in France over 3 decades ago.
The FY23 receivable amount for $11.7 million has been impaired by $4.5 million in FY24 to recognise management’s conservative approach to the portion of the tax claim related to overseas expenditure.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)